Evidence map›Paper›PMID 38293040›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis.

Camila Aparicio, Zachary I Willis, Mari M Nakamura, Joshua Wolf, Cordell Little, Gabriela M Maron, Paul K Sue, Brenda I Anosike, Christine Miller, Laura L Bio and 3 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Camila AparicioDepartment of Pediatrics, Yale University School of Medicine, New Haven, CT.
Zachary I WillisDepartment of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC.
Mari M NakamuraAntimicrobial Stewardship Program and Division of Infectious Diseases, Boston Children's Hospital, Boston, MA.
Joshua WolfDepartment of Infectious Diseases, St. Jude Children's Research Hospital and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN.
Cordell LittleDepartment of Pediatrics, Yale University School of Medicine, New Haven, CT.
Gabriela M MaronDepartment of Infectious Diseases, St. Jude Children's Research Hospital and Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN.
Paul K SueDepartment of Pediatrics, Columbia University Irving Medical Center, New York, NY.
Brenda I AnosikeDepartment of Pediatrics, The Children's Hospital at Montefiore and Albert Einstein College of Medicine, Bronx, NY.
Christine MillerDepartment of Pediatrics, Yale University School of Medicine, New Haven, CT.
Laura L BioDepartment of Pharmacy, Lucile Packard Children's Hospital, Stanford, CA.
Prachi SinghDepartment of Pediatrics, University of California San Francisco, San Francisco, CA.
Scott H JamesDepartment of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL.
Carlos R OliveiraDepartment of Pediatrics, Yale University School of Medicine, New Haven, CT.
Yale University · USSt. Jude Children's Research Hospital · USAlbert Einstein College of Medicine · USBoston Children's Hospital · USColumbia University Irving Medical Center · USLucile Packard Children's Hospital · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · US

Funding

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository CoreOT2HL161847 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GROSS, RACHEL SHARON, HORWITZ, LEORA · 2021 to 2025
$651.0M
NRSA Training CoreTL1TR001864 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$9.9M
Effectiveness of HPV Vaccine by Age at Immunization as Used in Clinical PracticeR01AI123204 · NIAID · YALE UNIVERSITY · PI NICCOLAI, LINDA M · 2017 to 2020
$1.8M
Clinical Epidemiology of Pediatric COVID-19 and MIS-CK23AI159518 · NIAID · YALE UNIVERSITY · PI OLIVEIRA, CARLOS RAFAEL · 2021 to 2024
$729k
NCATS NIH HHS TL1 TR001864NHLBI NIH HHS OT2 HL161847NIAID NIH HHS K23 AI159518NIAID NIH HHS R01 AI123204
6 · The paper itself

Abstract

Background: Risk stratification is a cornerstone of the Pediatric Infectious Diseases Society COVID-19 treatment guidance. This systematic review and meta-analysis aimed to define the clinical characteristics and comorbidities associated with critical COVID-19 in children and adolescents. Methods: Two independent reviewers screened the literature (Medline and EMBASE) for studies published through August 2023 that reported outcome data on patients aged ≤21 years with COVID-19. Critical disease was defined as an invasive mechanical ventilation requirement, intensive care unit admission, or death. Random effects models were used to estimate pooled odds ratios (OR) with 95% confidence intervals (CI), and heterogeneity was explored through subgroup analyses. Results: Among 10,178 articles, 136 studies met the inclusion criteria for review. Data from 70 studies, which collectively examined 172,165 children and adolescents with COVID-19, were pooled for meta-analysis. In previously healthy children, the absolute risk of critical disease from COVID-19 was 4% (95% CI, 1%-10%). Compared with no comorbidities, the pooled OR for critical disease was 3.95 (95% CI, 2.78-5.63) for presence of one comorbidity and 9.51 (95% CI, 5.62-16.06) for ≥2 comorbidities. Key risk factors included cardiovascular and neurological disorders, chronic pulmonary conditions (excluding asthma), diabetes, obesity, and immunocompromise, all with statistically significant ORs >2.00. Conclusions: While the absolute risk for critical COVID-19 in children and adolescents without underlying health conditions is relatively low, the presence of one or more comorbidities was associated with markedly increased risk. These findings support the importance of risk stratification in tailoring pediatric COVID-19 management.

Indexed as

comorbiditiesCOVID-19pediatricPredictors of severityrisk factors

Identifiers

PMID38293040
PMCPMC10827273
OpenAlexW4390965147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.